Sensitivity of L-(-)2',3'-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues

Biochemical Pharmacology

Volumn 57, Issue 12, 1999, Pages 1351-1359

  Fu, Lei ^a   Liu, Shwu Huey ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cross resistance; Hepatitis B virus (HBV); L( )SddC (3TC) resistance; Mutation; Nucleoside analogues

Indexed keywords

ADEFOVIR; CLEVUDINE; DNA POLYMERASE; ELVUCITABINE; FAMCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PENCICLOVIR;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DNA REPLICATION; DRUG RESISTANCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; PRIORITY JOURNAL; VIRUS MUTATION;

ACYCLOVIR; ADENINE; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HEPATITIS B VIRUS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; MUTATION; PHOSPHONIC ACIDS; ZALCITABINE;

EID: 0032951562     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00073-8     Document Type: Article

References (42)

1. Beasley R.P., Hwang L.Y., Lin C.C., Chien C.S. Hepatocellular carcinoma and hepatitis B virus A prospective study of 22,707 men in Taiwan . Lancet. ii:1981;1129-1136.
2. Gitlin N., Hepatitis B. Diagnosis, prevention, and treatment . Clin Chem. 43:1997;1500-1506.
3. Xu Z.Y., Duan S.C., Margolis H.S., Purcell R.H., Ou-Yang P.Y., Coleman P.J., Zhuang Y.L., Xu H.F., Qian S.G., Zhu Q.R., Wan C.Y., Liu C.B., Gun Z.L. Long-term efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection. J Infect Dis. 171:1995;54-60.
4. Wong D.K.H., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B A meta-analysis . Ann Intern Med. 119:1993;312-323.
5. Perrillo R.P., Schiff E.R., Davis G.L., Bodenheimer H.C. Jr, Lindsay K., Payne J., Dienstag J.L., O'Brien C., Tamburro C., Jacobson I.M., Sampliner R., Feit D., Lefkowitch J., Kuhns M., Meschievitz C., Sanghvi B., Albrecht J., Gibas A. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 323:1990;295-301.
6. Perrillo R.P. Treatment of chronic hepatitis B with interferon Experience in western countries . Semin Liver Dis. 9:1989;240-248.
7. Doong S.L., Tsai C.H., Schinazi R.F., Liotta D.C., Cheng Y.C. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA. 88:1991;8495-8499.
8. Tyrrell D.L.J., Fischer K., Savani K., Tan W., Jewell L. Treatment of chimpanzees and ducks with lamivudine, 2′,3′ dideoxy 3′ thiacytidine, results in a rapid suppression of hepaviral DNA in sera. Clin Invest Med. 16:(Suppl 4):1993;B77.
9. Honkoop P., de Man R.A., Zondervan P.E., Schalm S.W. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver. 17:1997;103-106.
10. Dienstag J.L., Perrillo R.P., Schiff E.R., Bartholomew M., Vicary C., Rubin M. A preliminary trial of lamivudine for chronic viral hepatitis B infection. N Engl J Med. 333:1995;1657-1661.
11. Hoofnagle J.H. Therapy of viral hepatitis. Digestion. 59:1998;563-578.
12. Fu L., Cheng Y.C. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol. 55:1998;1567-1572.
13. Hammer S.M., Katzenstein D.A., Hughes M.D., Gundacker H., Schooley R.T., Haubrich R.H., Henry W.K., Lederman M.M., Phair J.P., Niu M., Hirsch M.S., Merigan T.C. for the AIDS Clinical Trials Group Study 175 Study Team, A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 335:1996;1081-1090.
14. Johnson V.A., Merrill D.P., Videler J.A., Chou T.C., Byington R.E., Eron J.J., D'Aquila R.T., Hirsch M.S. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-α A inhibit replication of zidovudine-resistant human immunodeficiency virus type I synergistically in vitro. J Infect Dis. 164:1991;646-655.
15. St. Clair M., Pennington K.N., Rooney J., Barry D.W. Rapid screening of antiretroviral combinations. J Acquir Immune Defic Syndr. 10:(Suppl 1):1995;S24-S27.
16. Heijtink R.A., De Wilde G.A., Kruining J., Berk L., Balzarini J., De Clercq E., Holy A., Schalm S.W. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res. 21:1993;141-153.
17. Korba B., Boyd M. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother. 40:1996;1282-1284.
18. Shaw T., Mok S.S., Locarnini S.A. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology. 24:1996;996-1002.
19. Hung L.F., Brumbaugh A.E., Bhatia G., Marion P.L., Hung P.P., Norbeck D.W., Plattner J.J., Robinson W.S. Effects of purine nucleoside analogues with a cyclobutane ring and erythromycin A oxime derivatives on duck hepatitis B virus replication in vivo and in cell culture and HIV-1 in cell culture. J Med Virol. 35:1991;180-186.
20. Aye T.T., Bartholomeusz A., Shaw T., Bowden S., Breschkin A., McMillan J., Angus P., Locarnini S. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol. 26:1997;1148-1153.
21. Zoulim F, Pichoud C, Wang Z, Aguesse-Germon S and Trepo C, Hepatitis B virus genome variability during famciclovir therapy. Hepatology 26 (No 4, Pt 2): 428A, 1997.
22. Ling R., Mutimer D., Ahmed M., Boxall E.H., Elias E., Dusheiko G.M., Harrison T.J. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;711-713.
23. Tipples G.A., Ma M.M., Fischer K.P., Bain V.G., Kneteman N.M., Tyrrell D.L.J. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
24. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L.J. Brown N for the Lamivudine Clinical Investigation Group and Condreay LD, Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology. 27:1998;1670-1677.
25. Lin T.S., Luo M.Z., Liu M.C., Zhu Y.L., Gullen E., Dutschman G.E., Cheng Y.C. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine (β-L(-)d4C) and 2′,3′-dideoxy-2′,3′-didehydro-β-L-5-fluorocytidine (β-L(-)Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J Med Chem. 39:1996;1757-1759.
26. Pai S.B., Liu S.H., Zhu Y.L., Chu C.K., Cheng Y.C. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-β-L-arabinofuranosyl uracil. Antimicrob Agents Chemother. 40:1996;380-386.
27. Chu C.K., Ma T., Shanmuganathan K., Wang C., Xiang Y., Pai S.B., Yao G.Q., Sommadossi J.P., Cheng Y.C. Use of 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother. 39:1995;979-981.
28. Fu L., Wu X., Kong Y.Y., Wang Y. Regulation of hepatitis B virus gene expression by its enhancers. Acta Biochim Biophys Sin. 28:1996;590-599.
29. Fu L., Wu X., Kong Y.Y., Wang Y. Regulation of hepatitis B virus gene expression by core promoter and its upstream sequences. Chin J Virol. 13:1997;215-223.
30. Chang C.N., Doong S.L., Zhou J.H., Beach J.W., Jeong L.S., Chu C.K., Tsai C.H., Cheng Y.C. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem. 267:1992;13938-13942.
31. Bartholomew M.M., Jansen R.W., Jeffers L.J., Reddy K.R., Johnson L.C., Bunzendahl H., Condreay L.D., Tzakis A.G., Schiff E.R., Brown N.A. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 349:1997;20-22.
32. Chayama K., Suzuki Y., Kobayashi M., Kobayashi M., Tsubota A., Hashimoto M., Miyano Y., Koike H., Kobayashi M., Koida I., Arase Y., Saitoh S., Murashima N., Ikeda K., Kumada H. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy. Hepatology. 27:1998;1711-1716.
33. Liu S.H., Grove K.L., Cheng Y.C. Unique metabolism of a novel antiviral L-nucleoside analog, 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil A substrate for both thymidine kinase and deoxycytidine kinase . Antimicrob Agents Chemother. 42:1998;833-839.
34. Barry DW, New therapies in development for HIV/AIDS and HBV infection. Clinical Horizons: New approaches to the pharmacotherapy of HIV and HBV disease (Symposium Syllabus). July 1998, Geneva, Switzerland.
35. Locarnini S, The challenges of treating HBV disease. Clinical Horizons: New approaches to the pharmacotherapy of HIV and HBV disease (Symposium Syllabus). July 1998, Geneva, Switzerland.
36. Shields PL, Ling L, Harrison T, Boxall E, Elias E and Mutimer DJ, Management and outcome of lamivudine (LAM)-resistant hepatitis B virus (HBV) infection after liver transplantation (LT). Hepatology 26 (No 4, Pt 2): 260A, 1997.
37. Tillmann HL, Trautwein C, Bock T, Glowenka M, Kruger M, Boker K, Jackel E, Pichlmayr R, Condreay L, Bruns I, Deslaurias M, Gauthier J and Manns MP, Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation. Hepatology 26 (No 4, Pt 2): 429A, 1997.
38. Pichoud C., Seigneres B., Wang Z., Trepo C., Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology. 29:1999;230-237.
39. Gaillard RK, Allen MI, Miller WH, Barnard J and Condreay LD, In vitro evaluation of potential add-on therapeutics for the treatment of lamivudine treated patients infected with YMDD mutant HBV. Hepatology 27 (No 4, Pt 2): 318A, 1998.
40. Xiong X, Yang H, Westland CE, Toole JJ and Gibbs CS, Human hepatitis B virus DNA polymerases which contain mutations arising during famciclovir treatment remain sensitive to adefovir. Hepatology 27 (No 4, Pt 2): 491A, 1998.
41. Gilson RJC, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, Murray A, Jaffe HS and Weller IVD, Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection. Hepatology 27 (No 4, Pt 2): 491A, 1998.
42. Barditch-Crovo P., Toole J., Hendrix C.W., Cundy K.C., Ebeling D., Jaffe H.S., Lietman P.S. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis. 176:1997;406-413.